Malaria vaccines: into a mirror, darkly?

Trends in Parasitology

Volumn 24, Issue 12, 2008, Pages 532-536

  Plebanski, Magdalena ^a   Locke, Emily ^b   Kazura, James W ^c   Coppel, Ross L ^a,d  

^a MONASH UNIVERSITY   (Australia)

^b PATH Malaria Vaccine Initiative   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Victorian Bioinformatics Consortium   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RESEARCH; HUMAN; MALARIA; MALARIA CONTROL; PARASITE IMMUNITY;

HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM;

ANIMALIA;

EID: 55549145006     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2008.09.006     Document Type: Article

References (65)

1. Greenwood B.M., et al. Malaria. Lancet 365 (2005) 1487-1498
2. Plebanski M., et al. Economic and practical challenges to the formulation of vaccines against endemic infectious diseases such as malaria. Methods 40 (2006) 77-85
3. Gupta S., et al. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat. Med. 5 (1999) 340-343
4. Collins W.E., et al. Immunization of Saimiri sciureus boliviensis with recombinant vaccines based on the circumsporozoite protein of Plasmodium vivax. Am. J. Trop. Med. Hyg. 40 (1989) 455-464
5. Struik S.S., and Riley E.M. Does malaria suffer from lack of memory?. Immunol. Rev. 201 (2004) 268-290
6. Xiang S.D., et al. Promising particle-based vaccines in cancer therapy. Expert Rev. Vaccines 7 (2008) 1103-1119
7. Xiang S.D., et al. Pathogen recognition and development of particulate vaccines: does size matter?. Methods 40 (2006) 1-9
8. Luke T.C., and Hoffman S.L. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206 (2003) 3803-3808
9. + T cells. J. Infect. Dis. 196 (2007) 599-607
10. Kanoi B.N., and Egwang T.G. New concepts in vaccine development in malaria. Curr. Opin. Infect. Dis. 20 (2007) 311-316
11. Ripley Ballou W. Obstacles to the development of a safe and effective attenuated pre-erythrocytic stage malaria vaccine. Microbes Infect. 9 (2007) 761-766
12. Flanagan K.L., et al. Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assays. J. Immunol. 167 (2001) 4729-4737
13. Flanagan K.L., et al. Cellular reactivity to the P. falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. Am. J. Trop. Med. Hyg. 74 (2006) 367-375
14. Lee E.A., et al. Dimorphic Plasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming. Eur. J. Immunol. 36 (2006) 1168-1178
15. Plebanski M., et al. Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum. Immunity 10 (1999) 651-660
16. Plebanski M., et al. Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. Nat. Med. 5 (1999) 565-571
17. Gilbert S.C., et al. Association of malaria parasite population structure, HLA, and immunological antagonism. Science 279 (1998) 1173-1177
18. Alonso P.L., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 (2005) 2012-2018
19. Stoute J.A., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336 (1997) 86-91
20. Alonso P.L., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 (2004) 1411-1420
21. Kester K.E., et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 183 (2001) 640-647
22. Kester K.E., et al. Phase 2a trial of 0.1 and 3 month and 0,7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 26 (2008) 2191-2202
23. Genton B. Malaria vaccines: a toy for travelers or a tool for eradication?. Expert Rev. Vaccines 7 (2008) 597-611
24. Aponte J.J., et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 370 (2007) 1543-1551
25. + T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 10 (2004) 406-410
26. Dunachie S.J., et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun. 74 (2006) 5933-5942
27. Keating S.M., et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 175 (2005) 5675-5680
28. Webster D.P., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 4836-4841
29. Moorthy V.S., et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 1 (2004) e33
30. Pinzon-Charry A., and Good M.F. Malaria vaccines: the case for a whole-organism approach. Expert Opin. Biol. Ther. 8 (2008) 441-448
31. Epstein J.E., et al. Malaria vaccines: are we getting closer?. Curr. Opin. Mol. Ther. 9 (2007) 12-24
32. Genton B., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185 (2002) 820-827
33. Thompson F.M., et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One 3 (2008) e1493
34. Pouniotis D.S., et al. Dendritic cells induce immunity and long-lasting protection against blood-stage malaria despite an in vitro parasite-induced maturation defect. Infect. Immun. 72 (2004) 5331-5339
35. Chiang P.K., et al. Malaria: therapy, genes and vaccines. Curr. Mol. Med. 6 (2006) 309-326
36. McIntosh R.S., et al. The importance of human FcγRI in mediating protection to malaria. PLoS Pathog. 3 (2007) e72
37. 19-based immunisation regimens by measuring specific invasion inhibitory antibodies in mouse sera. Int. J. Parasitol. 38 (2008) S48
38. Todryk S.M., et al. Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS One 3 (2008) e2027
39. + T cell cycle arrest during priming as a consequence of dendritic cell interaction with Plasmodium-infected red cells. J. Immunol. 175 (2005) 3525-3533
40. Urban B.C., et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 400 (1999) 73-77
41. Hermsen C.C., et al. Glutamine-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in phase I malaria vaccine trial. Vaccine 25 (2007) 2930-2940
42. Reyburn H., et al. Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria. JAMA 293 (2005) 1461-1470
43. Dent A., et al. Prenatal malaria immune experience affects acquisition of Plasmodium falciparum merozoite surface protein-1 invasion inhibitory antibodies during infancy. J. Immunol. 177 (2006) 7139-7145
44. King C.L., et al. Acquired immune responses to Plasmodium falciparum merozoite surface protein-1 in the human fetus. J. Immunol. 168 (2002) 356-364
45. Malhotra I., et al. Distinct Th1- and Th2-Type prenatal cytokine responses to Plasmodium falciparum erythrocyte invasion ligands. Infect. Immun. 73 (2005) 3462-3470
46. Moormann A.M., et al. Stability of interferon-γ and interleukin-10 responses to Plasmodium falciparum liver stage antigen-1 and thrombospondin-related adhesive protein in residents of a malaria holoendemic area. Am. J. Trop. Med. Hyg. 74 (2006) 585-590
47. Elliott S.R., et al. Inhibition of dendritic cell maturation by malaria is dose dependent and does not require Plasmodium falciparum erythrocyte membrane protein 1. Infect. Immun. 75 (2007) 3621-3632
48. Sponaas A.M., et al. Malaria infection changes the ability of splenic dendritic cell populations to stimulate antigen-specific T cells. J. Exp. Med. 203 (2006) 1427-1433
49. Helmby H. Schistosomiasis and malaria: another piece of the crossreactivity puzzle. Trends Parasitol. 23 (2007) 88-90
50. Lyke K.E., et al. Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children. Am. J. Trop. Med. Hyg. 73 (2005) 1124-1130
51. John C.C., et al. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am. J. Trop. Med. Hyg. 73 (2005) 222-228
52. John C.C., et al. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J. Immunol. 173 (2004) 666-672
53. Luty A.J., et al. Interferon-γ responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J. Infect. Dis. 179 (1999) 980-988
54. Drakeley C.J., et al. Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 5108-5113
55. Li S., et al. Defining target antigens for CD25+ FOXP3 + IFN-γ- regulatory T cells in chronic hepatitis C virus infection. Immunol. Cell Biol. 85 (2007) 197-204
56. Wilson N.S., et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 7 (2006) 165-172
57. Bergmann-Leitner E.S., et al. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am. J. Trop. Med. Hyg. 75 (2006) 437-442
58. Lundquist R., et al. Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties. Infect. Immun. 74 (2006) 3222-3231
59. Yoon I.K., et al. Characterization of a human reference standard for antibody to Plasmodium falciparum merozoite surface protein 1(42). Am. J. Trop. Med. Hyg. 72 (2005) 714-718
60. Hollingdale M.R., et al. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J. Immunol. 132 (1984) 909-913
61. Hoffman S.L., et al. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science 244 (1989) 1078-1081
62. Tsuboi T., et al. Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. Infect. Immun. 76 (2008) 1702-1708
63. Corradin G., et al. Protein structure based strategies for antigen discovery and vaccine development against malaria and other pathogens. Endocr. Metab. Immune Disord. Drug Targets 7 (2007) 259-265
64. Duffy P.E., et al. Malaria vaccines: using models of immunity and functional genomics tools to accelerate the development of vaccines against Plasmodium falciparum. Vaccine 23 (2005) 2235-2242
65. Regis D.P., et al. Transcriptionally active PCR for antigen identification and vaccine development: in vitro genome-wide screening and in vivo immunogenicity. Mol. Biochem. Parasitol. 158 (2008) 32-45